Table 1 General clinicopathological characteristics of patients
From: EZR promotes pancreatic cancer proliferation and metastasis by activating FAK/AKT signaling pathway
Clinical epidemiology and clinicopathologic feature | N | EZR | P value | |
|---|---|---|---|---|
Low expression | High expression | |||
All cases | 26 | 11 | 15 | Â |
 Age |  |  |  | 0.453 |
  ≤ 60 | 12 | 4 | 8 |  |
  > 60 | 14 | 7 | 7 | |
 Gender |  |  |  | 0.689 |
  Male | 16 | 6 | 10 |  |
  Female | 10 | 5 | 5 | |
 Diameter of tumor |  |  |  | 0.701 |
  ≤ 3 | 15 | 7 | 8 |  |
  > 3 | 11 | 4 | 7 | |
 Tumor differentiation |  |  |  | 0.692 |
  Well/moderate | 14 | 5 | 9 |  |
  Poor | 12 | 6 | 6 | |
 Pathological T |  |  |  | 0.428 |
  T1/T2 | 16 | 8 | 8 |  |
  T3/T4 | 10 | 3 | 7 | |
 Lymph node metastasis |  |  |  | 0.021 |
  N0 (negative) | 14 | 9 | 5 |  |
  N1 (positive) | 12 | 2 | 10 | |
 TNM stage |  |  |  | 0.045 |
  I/II | 14 | 8 | 4 |  |
  III/IV | 13 | 3 | 11 | |
 Vessel invasion |  |  |  | 0.109 |
  Negative | 16 | 9 | 7 |  |
  Positive | 10 | 2 | 8 | |